The Journal of Nuclear Medicine最新文献

{"title":"Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study","authors":"Andrei Iagaru, Jose F. Suarez, Spencer Behr, Rahul Aggarwal, Pilar Paredes, Nicolo Buffi, Thomas Penhoat, Francesco Ceci, Jochen Walz, Nicolas Doumerc, Medge Coulanges, Zhongying Xu, Christelle Seigne, Celine Wilke, Ana M. Catafau, Stefano Fanti, Tobias Maurer, on behalf of the GuideView study investigators","doi":"10.2967/jnumed.124.269007","DOIUrl":"https://doi.org/10.2967/jnumed.124.269007","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269007absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT","authors":"Andrei Gafita, Jennifer A. Schroeder, Francesco Ceci, Jorge D. Oldan, Amir H. Khandani, Frederic E. Lecouvet, Lilja B. Solnes, Steven P. Rowe","doi":"10.2967/jnumed.124.268071","DOIUrl":"https://doi.org/10.2967/jnumed.124.268071","url":null,"abstract":"<p>In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)&ndash;targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA PET for purposes of initial staging, recurrence, and establishing eligibility for PSMA-targeted radiopharmaceutical therapy. Conventional imaging modalities, including bone scan and CT, are inadequate for identifying sites of PC in a variety of clinical scenarios. Further, current standardized response assessment approaches based on either conventional imaging or PET radiotracers that lack sensitivity for PC are inappropriate for response assessment in men with PC. There is currently no specific regulatory approval for the use of PSMA PET for response assessment. In the context of the use of PSMA-targeted radiopharmaceutical therapy and other cytotoxic therapeutic approaches, both the PSMA PET progression criteria and RECIP 1.0 have been shown to have value and to provide prognostic information. However, the role of those criteria is less clear for patients who are being treated with agents targeting the androgen signaling axis, given variable changes in PSMA expression. Ultimately, there may be key roles for machine learning and artificial intelligence in identifying imaging biomarkers based on changes in PSMA PET uptake during therapy.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials","authors":"Adrien Holzgreve, Lena M. Unterrainer, Maximilian Tiling, Nabeel Mansour, Christine Spitzweg, Matthias Brendel, Jens Ricke, Marcus Unterrainer, Wolfgang G. Kunz, Dirk Mehrens","doi":"10.2967/jnumed.124.269416","DOIUrl":"https://doi.org/10.2967/jnumed.124.269416","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269416absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI","authors":"Ameer Mansur, Jonathan E. McConathy, Erica Stringer-Reasor, Gabrielle Rocque, Katia Khoury, Noon Eltoum, Moozhan Nikpanah, Jennifer Bartels, Brian Wright, Nusrat Jahan, Denise Jeffers, Suzanne E. Lapi, Anna G. Sorace","doi":"10.2967/jnumed.124.268931","DOIUrl":"https://doi.org/10.2967/jnumed.124.268931","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268931absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein–Targeted Imaging—FAP-RADS Version 1.0","authors":"Emil Novruzov, Gabriel T. Sheikh, Eduards Mamlins, Adrien Holzgreve, Yuriko Mori, Stephan Ledderose, Frederik Klauschen, Tadashi Watabe, Michael A. Gorin, Martin G. Pomper, Ken Herrmann, Steven P. Rowe, Rudolf A. Werner, Frederik L. Giesel","doi":"10.2967/jnumed.125.269914","DOIUrl":"https://doi.org/10.2967/jnumed.125.269914","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269914absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"402 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Efficacy of [18F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study","authors":"Stefano Fanti, Javier Jesus Robles Barba, Spencer Behr, Tobias Maurer, Pilar Paredes, Jochen Walz, Joan Duch, Marc Simo Perdigo, Ismini Charis Mainta, Pierre Benoit Bonnefoy, Medge Coulanges, Jun Tang, Christelle Seigne, Celine Wilke, Ana M. Catafau, Andrei Iagaru, Rahul Aggarwal","doi":"10.2967/jnumed.124.269266","DOIUrl":"https://doi.org/10.2967/jnumed.124.269266","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269266absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Short-Term Redifferentiation in Patients with Radioactive Iodine–Refractory Metastatic Thyroid Cancer","authors":"Johannes von Hinten, Oliver Viering, Ralph A. Bundschuh, Feyza Cagliyan, Hermann Wengenmair, Christian H. Pfob, James Nagarajah, Constantin Lapa, Malte Kircher","doi":"10.2967/jnumed.125.270055","DOIUrl":"https://doi.org/10.2967/jnumed.125.270055","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.270055absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2–Expressing Breast Cancer","authors":"Sara S. Rinne, Daniela Burnes Vargas, Shin Seo, Darren Veach, Michael R. McDevitt, Brett A. Vaughn, Hong Xu, Hong-Fen Guo, Edward K. Fung, Elisa de Stanchina, Ileana C. Miranda, Steven M. Larson, Nai Kong V. Cheung, Sarah M. Cheal","doi":"10.2967/jnumed.125.269601","DOIUrl":"https://doi.org/10.2967/jnumed.125.269601","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269601absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer","authors":"Tihomir Zh. Todorov, Ricardo Coelho, Sharon Dellea, Francis Jacob, Viola Heinzelmann-Schwarz, Pascal V. Grundler, Nicholas P. van der Meulen, Martin P. Béhé, Roger Schibli, Jürgen Grünberg","doi":"10.2967/jnumed.124.269078","DOIUrl":"https://doi.org/10.2967/jnumed.124.269078","url":null,"abstract":"&lt;p&gt;Cancer stem cells (CSCs) are highly tumorigenic, self-renewable cells with a key role in tumor relapse, metastasis, and therapy resistance. Effective CSC-targeted therapies remain an unmet clinical need, strongly dependent on the selection of suitable targets and thorough validation of therapeutic agents. L1 cell adhesion molecule (L1CAM) is a targetable CSC-associated biomarker aberrantly expressed in various malignancies, including ovarian cancer (OC). &lt;sup&gt;161&lt;/sup&gt;Tb is attractive for clinical application because of its substantial emission of conversion electrons/Auger electrons as well as β&lt;sup&gt;–&lt;/sup&gt; emission. Leveraging the high cytotoxicity of conversion electrons/Auger electrons, &lt;sup&gt;161&lt;/sup&gt;Tb is promising for radioimmunotherapy against radioresistant tumor cells such as CSCs. The aim of this study was to confirm the presence of L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; ovarian CSCs in patient samples and preclinically investigate, in a tumor prevention mouse model, &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM radioimmunotherapy as a new therapeutic modality against CSCs compared with &lt;sup&gt;177&lt;/sup&gt;Lu-based anti-L1CAM radioimmunotherapy. &lt;strong&gt;Methods&lt;/strong&gt;: L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs were examined in OC samples by immunofluorescence. After radiolabeling anti-L1CAM DOTA-chCE7 with &lt;sup&gt;177&lt;/sup&gt;Lu or &lt;sup&gt;161&lt;/sup&gt;Tb and purification, we assessed radioimmunoconjugate quality by determining the radiochemical purity and the immunoreactive fraction. The internalized and membrane-bound fractions and the radiocytotoxicity of radiolabeled DOTA-chCE7 were evaluated with cell uptake and cell proliferation assays. Ovarian L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs were sorted via fluorescence-activated cell sorting from OVCAR8 and SKOV3ip cells and inoculated into immunocompromised mice, who then received treatment with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 or [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7. &lt;strong&gt;Results&lt;/strong&gt;: L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs (0.3%–21%) were confirmed in samples from patients who were chemotherapy-naïve or had relapsed OC. [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 and [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7 were produced with high radiochemical purity and retained 76%–96% immunoreactivity. Cell uptake after 15 h ranged from 50% to 75% for both radioimmunoconjugates. [&lt;sup&gt;161&lt;/sup&gt;Tb]Tb-DOTA-chCE7 showed significantly increased cytotoxicity, eliminating all ovarian CSCs and tumor cells differentiated from the CSCs in vivo, compared with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-DOTA-chCE7 (3 tumors in OVCAR8 group and 1 tumor in SKOV3ip group). Follow-up tumor analysis confirmed that sorted ovarian L1CAM&lt;sup&gt;+&lt;/sup&gt;/CD133&lt;sup&gt;+&lt;/sup&gt; CSCs regenerated the tumor heterogeneity in vivo. &lt;strong&gt;Conclusion&lt;/strong&gt;: This work addresses the critical need for CSC-specific therapies in the clinics by establishing &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM radioimmunotherapy as a novel therapeutic modality against CSCs. We found that &lt;sup&gt;161&lt;/sup&gt;Tb-based anti-L1CAM ","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients","authors":"Stefan Schmitl, Elisabeth Kretschmer-Chott, Eva-Maria Patronas, Gero Kramer, Philipp Ritt, Elisabeth Fuchs, Maximilian Weisbrod, Lukas Nics, Markus Mitterhauser, Marcus Hacker","doi":"10.2967/jnumed.125.269655","DOIUrl":"https://doi.org/10.2967/jnumed.125.269655","url":null,"abstract":"<p>²²⁵Ac-labeled (<em>S</em>)-ibuprofen-diaminobutyric acid-PSMA (SibuDAB) is a novel, albumin-binding compound in prostate-specific membrane antigen (PSMA)–targeted α-therapy of prostate cancer. It showed superior preclinical efficacy results to [²²⁵Ac]Ac-PSMA-617. ²²⁵Ac decays via multiple α-particle emissions. The full therapeutic potential requires fast tumor uptake and retention of parent and daughter nuclides, such as ²¹³Bi, in the tumor. High decay energies lead to daughter nuclide recoil of the chelator and, therefore, altered pharmacokinetics and potential irradiation of off-target organs. We hereby present clinical efficacy and safety data for [²²⁵Ac]Ac-SibuDAB, as well as blood kinetics and the ²¹³Bi distribution between blood and urine samples. <strong>Methods:</strong> Fifteen prostate cancer patients who received [²²⁵Ac]Ac-SibuDAB between December 2021 and August 2024 were included in this retrospective study. Patients were scheduled to receive 6 MBq of [²²⁵Ac]Ac-SibuDAB every 8 wk. The prostate-specific antigen (PSA) response was evaluated, and adverse events were categorized according to Common Terminology Criteria for Adverse Events, version 5.0. Blood pharmacokinetics were determined after blood sampling at different time points and measured in ²²⁵Ac/²²¹Fr equilibrium. The ²¹³Bi distribution was determined in blood and urine samples before reaching ²²⁵Ac/²¹³Bi equilibrium. <strong>Results:</strong> Fifteen patients received a total of 25 cycles with a median exposure of 6.55 MBq (range, 4.65–30.60 MBq). The Gleason score was available for 12 of the 15 patients, with 10 patients having a Gleason score of 8 or higher. The patients were heavily pretreated, including 13 patients with prior [¹⁷⁷Lu]Lu-PSMA therapy. Nine of the 15 patients showed any PSA decline, and 5 of the 15 patients showed a PSA decline of 50% or more. All patients showed grade 1 xerostomia. Treatment was stopped because of grade 3 thrombocytopenia in 1 of the 15 patients. [²²⁵Ac]Ac-SibuDAB blood kinetics were evaluated in 6 patients. ²¹³Bi blood and urine distribution studies were conducted on 3 patients and showed a vast net ²¹³Bi excess in urine immediately after application, a moderate excess at later time points, and a lack of ²¹³Bi in blood at any time point. <strong>Conclusion:</strong> [²²⁵Ac]Ac-SibuDAB initial clinical data show efficacy in heavily pretreated prostate cancer patients, with 1 patient experiencing treatment-limiting toxicity. Only limited signs of xerostomia were observed after the treatment. ²¹³Bi generated by recoil is rapidly distributed into urine after application of [²²⁵Ac]Ac-SibuDAB.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"248 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}